Amphastar Pharmaceuticals Company Profile (NASDAQ:AMPH)

About Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals logoAmphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AMPH
  • CUSIP: N/A
  • Web: www.amphastar.com
Capitalization:
  • Market Cap: $743.74 million
  • Outstanding Shares: 46,195,000
Average Prices:
  • 50 Day Moving Avg: $15.56
  • 200 Day Moving Avg: $15.82
  • 52 Week Range: $12.05 - $21.75
P/E:
  • Trailing P/E Ratio: 209.09
  • Foreward P/E Ratio: 24.03
  • P/E Growth: 2.43
Sales & Book Value:
  • Annual Revenue: $249.62 million
  • Price / Sales: 2.98
  • Book Value: $7.21 per share
  • Price / Book: 2.23
Profitability:
  • EBIDTA: $17.41 million
  • Net Margins: 1.61%
  • Return on Equity: 2.42%
  • Return on Assets: 1.84%
Debt:
  • Debt-to-Equity Ratio: 0.12%
  • Current Ratio: 3.04%
  • Quick Ratio: 1.87%
Misc:
  • Average Volume: 200,017 shs.
  • Beta: 1.66
  • Short Ratio: 15.13
 

Frequently Asked Questions for Amphastar Pharmaceuticals (NASDAQ:AMPH)

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

How will Amphastar Pharmaceuticals' stock buyback program work?

Amphastar Pharmaceuticals announced that its board has initiated a stock buyback plan on Thursday, August 10th 2017, which permits the company to buyback $20,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to purchase up to 2.8% of its shares through open market purchases. Shares buyback plans are often an indication that the company's management believes its stock is undervalued.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) issued its quarterly earnings results on Wednesday, August, 9th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.05. The business earned $65.20 million during the quarter, compared to analyst estimates of $63.40 million. Amphastar Pharmaceuticals had a return on equity of 2.42% and a net margin of 1.61%. The business's revenue for the quarter was down 4.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.23 earnings per share. View Amphastar Pharmaceuticals' Earnings History.

Where is Amphastar Pharmaceuticals' stock going? Where will Amphastar Pharmaceuticals' stock price be in 2017?

6 brokerages have issued 12 month price objectives for Amphastar Pharmaceuticals' stock. Their predictions range from $16.00 to $29.00. On average, they anticipate Amphastar Pharmaceuticals' share price to reach $19.83 in the next twelve months. View Analyst Ratings for Amphastar Pharmaceuticals.

What are analysts saying about Amphastar Pharmaceuticals stock?

Here are some recent quotes from research analysts about Amphastar Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. " (5/16/2017)
  • 2. Piper Jaffray Companies analysts commented, "Amphastar reported 4Q16 diluted EPS of $0.01 on revenues of $63.5M, compared to Street estimates of ($0.01) and $55.9M, respectively. Though the base business is facing some challenges as we move further into 2017 (i.e., uncertainty over the trajectory of generic enoxaparin; the potential removal of AMPH's injectable epinephrine given that it is an unapproved product), we nonetheless remain bullish on AMPH shares, given that the pipeline continues to advance and given our view that it very much has the potential to drive transformative longer-term cash generation (AMPH also being one of the few generics companies solely focused on more complex dosage forms also doesn't hurt). We reiterate our Overweight rating and are lowering our PT to $20 from $22 (see below for more details)." (3/14/2017)
  • 3. BMO Capital Markets analysts commented, " AMPH reported 4Q16 revenue of $63.5mm vs. BMO/consensus $56.5mm/ $55.9mm and adj. EPS of $0.01 vs. BMO/consensus $0.02/($0.01). Revenue upside was offset by lower gross margin and higher R&D. Without 2017 revenue/EPS guidance, there is some uncertainty with the numbers given a number of moving parts, including Enoxaparin sales, potential withdrawal of Epinephrine vials, overall pricing pressure, contribution from new approvals, and higher spending levels to invest in the pipeline. We are lowering estimates and our target goes to $16 from $18. The pipeline has value, but we await near-term execution." (3/14/2017)
  • 4. Needham & Company LLC analysts commented, "While AMPH reported 4Q16 results that bested the Street's expectations on both top and bottom lines, the company has taken its lumps from the FDA over the last three months. Two recent CRLs (Primatene Mist and intranasal naloxone) have delayed two branded product opportunities by at least 12 months. FDA recently requested that AMPH discontinue the distribution of its epinephrine vial product, which generated $18.6MM in 2016 revenues. The last shot on goal in terms of potential near-term approvals is an ANDA product (undisclosed injectable), which AMPH mgmt expects will make meaningful sales contributions in 2017. The ANDA product pipeline is expected to make additional contributions in 2018. We maintain our Buy rating and adjust our PT to $18 (from $20) to account for a reduction in base business revenues." (3/14/2017)

Who are some of Amphastar Pharmaceuticals' key competitors?

Who are Amphastar Pharmaceuticals' key executives?

Amphastar Pharmaceuticals' management team includes the folowing people:

  • Mary Ziping Luo Ph.D., Chief Operating Officer, Chief Scientist and Chairman of the Board
  • Jason B. Shandell J.D., President, General Counsel, Director
  • Jack Yongfeng Zhang Ph.D., Chief Executive Officer, Chief Scientific Officer, Director
  • William J. Peters, Chief Financial Officer, Senior Vice President, Treasurer and President of Armstrong Pharmaceuticals, Inc.
  • Diane G. Gerst, Executive Vice President - Quality Assurance and Regulatory Affairs and President of Amphastar Nanjing Pharmaceuticals Inc
  • Rong Zhou, Executive Vice President - Production Center and President of Armstrong Pharmaceuticals, Inc.
  • Michael A. Zasloff M.D. Ph.D., Lead Independent Director
  • Richard Koo CPA, Independent Director
  • Howard S. Lee Ph.D., Independent Director
  • Floyd F. Petersen, Independent Director

Who owns Amphastar Pharmaceuticals stock?

Amphastar Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.80%), Vanguard Group Inc. (5.28%), Dimensional Fund Advisors LP (2.91%), Federated Investors Inc. PA (2.29%), State Street Corp (2.10%) and Teachers Advisors LLC (1.20%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Rong Zhou, Stephen B Shohet and William J Peters. View Institutional Ownership Trends for Amphastar Pharmaceuticals.

Who sold Amphastar Pharmaceuticals stock? Who is selling Amphastar Pharmaceuticals stock?

Amphastar Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Rothschild Asset Management Inc., Citadel Advisors LLC, Acadian Asset Management LLC, Cornerstone Capital Management Holdings LLC., BlackRock Inc., JPMorgan Chase & Co., State Street Corp and Russell Investments Group Ltd.. Company insiders that have sold Amphastar Pharmaceuticals stock in the last year include Diane G Gerst, Floyd F Petersen, Howard Lee, Jason B Shandell, Michael A Zasloff, Richard K Prins and Rong Zhou. View Insider Buying and Selling for Amphastar Pharmaceuticals.

Who bought Amphastar Pharmaceuticals stock? Who is buying Amphastar Pharmaceuticals stock?

Amphastar Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Vanguard Group Inc., UBS Asset Management Americas Inc., Citigroup Inc., Bank of Montreal Can, Argent Capital Management LLC, Fisher Asset Management LLC and State of Wisconsin Investment Board. View Insider Buying and Selling for Amphastar Pharmaceuticals.

How do I buy Amphastar Pharmaceuticals stock?

Shares of Amphastar Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amphastar Pharmaceuticals' stock price today?

One share of Amphastar Pharmaceuticals stock can currently be purchased for approximately $16.10.


MarketBeat Community Rating for Amphastar Pharmaceuticals (NASDAQ AMPH)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  141 (Vote Outperform)
Underperform Votes:  100 (Vote Underperform)
Total Votes:  241
MarketBeat's community ratings are surveys of what our community members think about Amphastar Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Amphastar Pharmaceuticals (NASDAQ:AMPH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $19.83 (23.19% upside)

Analysts' Ratings History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/17/2017Piper Jaffray CompaniesReiterated RatingBuy$19.00LowView Rating Details
8/11/2017Jefferies Group LLCReiterated RatingBuy$20.00 -> $19.00LowView Rating Details
7/31/2017BMO Capital MarketsReiterated RatingHold$16.00LowView Rating Details
7/22/2017Wells Fargo & CompanyReiterated RatingBuyMediumView Rating Details
3/14/2017Raymond James Financial, Inc.DowngradeStrong-Buy -> Outperform$21.00 -> $18.00HighView Rating Details
3/14/2017Needham & Company LLCLower Price TargetBuy$20.00 -> $18.00HighView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Earnings by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Earnings History by Quarter for Amphastar Pharmaceuticals (NASDAQ AMPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017$0.06$0.11$63.40 million$65.20 millionViewListenView Earnings Details
5/8/2017Q1 2017$0.06$0.03$63.74 million$56.67 millionViewListenView Earnings Details
3/13/2017Q4 2016($0.01)$0.01$55.78 million$63.54 millionViewN/AView Earnings Details
11/8/2016Q3$0.03$0.14$65.12 million$64.20 millionViewListenView Earnings Details
8/8/2016Q2$0.01$0.23$62.10 million$68.00 millionViewN/AView Earnings Details
5/9/2016Q1($0.03)$0.12$62.00 million$59.40 millionViewN/AView Earnings Details
3/14/2016Q415($0.04)$0.19$64.48 million$76.90 millionViewN/AView Earnings Details
11/12/2015Q315($0.20)($0.01)$19.49 million$63.90 millionViewListenView Earnings Details
8/12/2015Q215($0.11)($0.09)$19.49 million$53.85 millionViewListenView Earnings Details
5/13/2015Q115($0.17)($0.01)$45.87 million$56.89 millionViewListenView Earnings Details
3/24/2015Q414($0.06)($0.03)$54.90 million$55.90 millionViewN/AView Earnings Details
11/12/2014Q314($0.11)($0.11)$45.89 million$59.70 millionViewN/AView Earnings Details
8/12/2014Q2 2014($0.11)$0.02$44.23 million$49.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Amphastar Pharmaceuticals (NASDAQ:AMPH)
2017 EPS Consensus Estimate: $0.41
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.09$0.09$0.09
Q2 20171$0.04$0.04$0.04
Q3 20171$0.10$0.10$0.10
Q4 20171$0.18$0.18$0.18
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Insider Ownership Percentage: 11.10%
Institutional Ownership Percentage: 44.26%
Insider Trades by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Insider Trades by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2017Richard K PrinsDirectorSell10,000$14.81$148,100.00View SEC Filing  
8/14/2017Richard K PrinsDirectorSell5,000$14.80$74,000.00View SEC Filing  
6/9/2017Richard K PrinsDirectorSell10,000$17.07$170,700.00View SEC Filing  
6/1/2017Michael A ZasloffDirectorSell15,000$17.01$255,150.00View SEC Filing  
5/31/2017Jason B ShandellDirectorSell11,482$16.92$194,275.44View SEC Filing  
5/11/2017Richard K PrinsDirectorSell7,500$15.43$115,725.00View SEC Filing  
1/3/2017Floyd F PetersenDirectorSell400$18.61$7,444.00View SEC Filing  
12/15/2016Diane G GerstEVPSell2,940$20.51$60,299.40View SEC Filing  
12/5/2016Rong ZhouEVPSell61$20.70$1,262.70View SEC Filing  
12/1/2016Floyd F PetersenDirectorSell400$20.26$8,104.00View SEC Filing  
11/28/2016Jason B ShandellInsiderSell26,335$20.48$539,340.80View SEC Filing  
11/15/2016Howard LeeDirectorSell37,994$20.65$784,576.10View SEC Filing  
10/3/2016Floyd F PetersenDirectorSell400$18.75$7,500.00View SEC Filing  
9/26/2016Jason B ShandellInsiderSell56,996$19.50$1,111,422.00View SEC Filing  
9/20/2016Jack Y ZhangCEOSell444,199$21.03$9,341,504.97View SEC Filing  
9/8/2016Floyd F PetersenDirectorSell3,000$19.05$57,150.00View SEC Filing  
9/1/2016Howard LeeDirectorSell10,381$18.78$194,955.18View SEC Filing  
8/22/2016Jason B ShandellGeneral CounselSell10,000$19.95$199,500.00View SEC Filing  
8/19/2016Diane G GerstEVPSell24,046$19.28$463,606.88View SEC Filing  
8/18/2016Richard K PrinsDirectorSell3,086$19.62$60,547.32View SEC Filing  
8/17/2016Jason B ShandellInsiderSell5,987$18.86$112,914.82View SEC Filing  
8/16/2016Stephen B ShohetDirectorSell48,375$18.24$882,360.00View SEC Filing  
8/15/2016Michael A ZasloffDirectorSell48,375$18.15$878,006.25View SEC Filing  
8/12/2016William J PetersCFOSell1,027$18.19$18,681.13View SEC Filing  
8/11/2016Jason B ShandellPresidentSell5,636$18.01$101,504.36View SEC Filing  
8/11/2016Richard K PrinsDirectorSell13,993$18.03$252,293.79View SEC Filing  
7/18/2016William J PetersCFOSell2,297$17.76$40,794.72View SEC Filing  
6/15/2016Rong ZhouEVPSell1,551$15.85$24,583.35View SEC Filing  
6/13/2016Richard K PrinsDirectorSell7,500$15.94$119,550.00View SEC Filing  
6/9/2016Jason B ShandellPresidentSell9,904$16.43$162,722.72View SEC Filing  
6/2/2016William J PetersCFOSell2,297$16.00$36,752.00View SEC Filing  
5/25/2016Jason B ShandellPresidentSell1,074$15.60$16,754.40View SEC Filing  
5/18/2016Diane G GerstEVPSell1,427$13.97$19,935.19View SEC Filing  
5/17/2016Richard K PrinsDirectorSell3,200$13.56$43,392.00View SEC Filing  
4/19/2016Diane G GerstEVPSell21,244$12.89$273,835.16View SEC Filing  
4/18/2016Diane G GerstEVPSell15,637$12.83$200,622.71View SEC Filing  
3/17/2016Richard K PrinsDirectorSell2,400$11.25$27,000.00View SEC Filing  
12/17/2015Stephen B. ShohetDirectorSell30,770$14.19$436,626.30View SEC Filing  
12/16/2015Howard LeeDirectorSell38,462$14.34$551,545.08View SEC Filing  
12/16/2015Rong ZhouEVPSell772$14.29$11,031.88View SEC Filing  
12/11/2015Jack Y ZhangCEOSell63,300$14.25$902,025.00View SEC Filing  
12/8/2015Jack Y ZhangCEOSell68,117$14.71$1,002,001.07View SEC Filing  
12/3/2015Jack Y ZhangCEOSell38,583$15.45$596,107.35View SEC Filing  
8/18/2015Richard K PrinsDirectorSell9,100$14.66$133,406.00View SEC Filing  
8/17/2015Richard K. PrinsDirectorSell5,400$14.70$79,380.00View SEC Filing  
7/17/2015Michael A ZasloffDirectorSell7,692$17.41$133,917.72View SEC Filing  
6/17/2015Rong ZhouEVPSell1,000$16.48$16,480.00View SEC Filing  
6/15/2015Jack Y ZhangCEOSell45,382$16.29$739,272.78View SEC Filing  
6/12/2015Jack Y ZhangCEOSell160,495$16.23$2,604,833.85View SEC Filing  
6/9/2015Jack Y ZhangCEOSell193,758$16.43$3,183,443.94View SEC Filing  
5/22/2015Richard K PrinsDirectorSell29,452$14.77$435,006.04View SEC Filing  
5/19/2015Richard K PrinsDirectorSell3,000$14.94$44,820.00View SEC Filing  
4/9/2015Marilyn J PurchaseVPSell28,000$15.79$442,120.00View SEC Filing  
4/8/2015Diane G GerstSVPSell10,000$15.79$157,900.00View SEC Filing  
8/25/2014Howard LeeDirectorBuy6,000$10.84$65,040.00View SEC Filing  
8/19/2014Michael A ZasloffDirectorBuy3,500$10.00$35,000.00View SEC Filing  
8/18/2014Richard K PrinsDirectorBuy4,000$10.02$40,080.00View SEC Filing  
8/15/2014Floyd F PetersenDirectorBuy3,200$10.35$33,120.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Latest Headlines for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Source:
DateHeadline
baystreet.ca logoAmphastar Jumps on FDA Approval
www.baystreet.ca - September 22 at 7:21 PM
reuters.com logoBRIEF-Amphastar Pharmaceuticals receives FDA approval for sodium bicarbonate injection
www.reuters.com - September 22 at 7:21 PM
finance.yahoo.com logoAmphastar Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AMPH-US : September 22, 2017
finance.yahoo.com - September 22 at 2:18 PM
finance.yahoo.com logoETFs with exposure to Amphastar Pharmaceuticals, Inc. : September 22, 2017
finance.yahoo.com - September 22 at 2:17 PM
globenewswire.com logoAmphastar Pharmaceuticals Receives FDA Approval for Sodium Bicarbonate Injection - GlobeNewswire (press release)
globenewswire.com - September 20 at 9:02 PM
finance.yahoo.com logoAmphastar Pharmaceuticals Receives FDA Approval for Sodium Bicarbonate Injection
finance.yahoo.com - September 20 at 9:02 PM
americanbankingnews.com logo$56.54 Million in Sales Expected for Amphastar Pharmaceuticals, Inc. (AMPH) This Quarter
www.americanbankingnews.com - September 17 at 1:38 PM
americanbankingnews.com logoAmphastar Pharmaceuticals, Inc. (AMPH) Receives Buy Rating from Piper Jaffray Companies
www.americanbankingnews.com - September 17 at 7:06 AM
americanbankingnews.com logoAmphastar Pharmaceuticals, Inc. (AMPH) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - September 16 at 6:46 PM
thestreet.com logoThe national program aims to reduce the volume of opioids prescribed following wisdom tooth extraction by 50 percent
www.thestreet.com - September 13 at 5:01 PM
finance.yahoo.com logoETFs with exposure to Amphastar Pharmaceuticals, Inc. : September 12, 2017
finance.yahoo.com - September 11 at 9:54 PM
americanbankingnews.com logoComparing Merck & (MRK) & Amphastar Pharmaceuticals (AMPH)
www.americanbankingnews.com - September 10 at 4:12 AM
finance.yahoo.com logoAmphastar Pharmaceuticals, Inc. :AMPH-US: Earnings Analysis: Q2, 2017 By the Numbers : September 8, 2017
finance.yahoo.com - September 8 at 4:17 PM
americanbankingnews.com logoReviewing Amphastar Pharmaceuticals (AMPH) and Bristol-Myers Squibb (BMY)
www.americanbankingnews.com - September 6 at 2:10 AM
americanbankingnews.com logoHead to Head Review: Amphastar Pharmaceuticals (AMPH) and BioLife Solutions (BLFS)
www.americanbankingnews.com - August 29 at 2:16 AM
americanbankingnews.com logoAmphastar Pharmaceuticals, Inc. (AMPH) Lowered to Sell at ValuEngine
www.americanbankingnews.com - August 22 at 10:36 PM
americanbankingnews.com logoAmphastar Pharmaceuticals, Inc. (AMPH) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 22 at 9:06 PM
americanbankingnews.com logoCollegium Pharmaceutical (COLL) and Amphastar Pharmaceuticals (AMPH) Critical Survey
www.americanbankingnews.com - August 18 at 10:18 PM
americanbankingnews.com logoAmphastar Pharmaceuticals, Inc. (AMPH) Director Sells $74,000.00 in Stock
www.americanbankingnews.com - August 16 at 9:14 PM
americanbankingnews.com logoAmphastar Pharmaceuticals, Inc. (AMPH) Director Richard K. Prins Sells 10,000 Shares
www.americanbankingnews.com - August 16 at 8:46 PM
bloomberg.com logoSynthetic Heroin Is Too Powerful for the Overdose Antidote
www.bloomberg.com - August 16 at 3:56 PM
finance.yahoo.com logoAmphastar Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AMPH) : August 15, 2017
finance.yahoo.com - August 15 at 9:52 PM
americanbankingnews.com logoAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Downgraded to "Sell" at BidaskClub
www.americanbankingnews.com - August 13 at 2:38 PM
americanbankingnews.com logoAmphastar Pharmaceuticals, Inc. (AMPH) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - August 11 at 6:20 PM
americanbankingnews.com logo$68.67 Million in Sales Expected for Amphastar Pharmaceuticals, Inc. (AMPH) This Quarter
www.americanbankingnews.com - August 11 at 4:04 PM
finance.yahoo.com logoEdited Transcript of AMPH earnings conference call or presentation 9-Aug-17 9:00pm GMT
finance.yahoo.com - August 10 at 5:15 PM
americanbankingnews.com logoAmphastar Pharmaceuticals, Inc. (AMPH) Posts Earnings Results, Beats Expectations By $0.05 EPS
www.americanbankingnews.com - August 10 at 3:42 PM
americanbankingnews.com logoAmphastar Pharmaceuticals (AMPH) to Repurchase $20.00 million in Stock
www.americanbankingnews.com - August 10 at 12:20 PM
americanbankingnews.com logoAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Given a $19.00 Price Target by Piper Jaffray Companies Analysts
www.americanbankingnews.com - August 10 at 9:08 AM
nasdaq.com logoAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2017 - Nasdaq
www.nasdaq.com - August 9 at 9:04 PM
finance.yahoo.com logoAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2017
finance.yahoo.com - August 9 at 9:04 PM
finance.yahoo.com logoAmphastar beats 2Q profit forecasts
finance.yahoo.com - August 9 at 9:04 PM
globenewswire.com logoAmphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 9, 2017 - GlobeNewswire (press release)
globenewswire.com - August 4 at 9:12 PM
nasdaq.com logoAmphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 9, 2017 - Nasdaq
www.nasdaq.com - August 2 at 3:45 PM
feeds.benzinga.com logoAmphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 9, 2017
feeds.benzinga.com - August 2 at 6:43 AM
finance.yahoo.com logoAmphastar Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMPH-US : August 1, 2017
finance.yahoo.com - August 1 at 4:49 PM
americanbankingnews.com logoAmphastar Pharmaceuticals' (NASDAQ:AMPH) Hold Rating Reaffirmed at BMO Capital Markets
www.americanbankingnews.com - July 31 at 9:41 AM
americanbankingnews.com logoPiper Jaffray Companies Analysts Give Amphastar Pharmaceuticals, Inc. (AMPH) a $20.00 Price Target
www.americanbankingnews.com - July 30 at 11:36 AM
americanbankingnews.com logoBidaskClub Downgrades Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) to Hold
www.americanbankingnews.com - July 29 at 9:52 PM
americanbankingnews.com logoAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 28 at 9:09 PM
seekingalpha.com logoAmphastar announces jury verdict in patent litigation against Momenta Pharmaceuticals and Sandoz
seekingalpha.com - July 25 at 4:53 AM
nasdaq.com logoAmphastar Announces Jury Verdict in Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc. - Nasdaq
www.nasdaq.com - July 24 at 1:17 PM
finance.yahoo.com logoAmphastar Announces Jury Verdict in Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc.
finance.yahoo.com - July 24 at 1:17 PM
americanbankingnews.com logoAmphastar Pharmaceuticals, Inc. (AMPH) Receives Buy Rating from Wells Fargo & Company
www.americanbankingnews.com - July 23 at 11:14 PM
reuters.com logoUS jury sides with Amphastar over Momenta in drug patent trial - Reuters
www.reuters.com - July 22 at 3:29 AM
nasdaq.com logoMomenta Pharmaceuticals Announces Jury Verdict in Enoxaparin Sodium Injection Patent Litigation Against Amphastar
www.nasdaq.com - July 21 at 5:26 PM
finance.yahoo.com logo​Jury nixes Momenta patent case that sought $938M in damages
finance.yahoo.com - July 21 at 5:26 PM
finance.yahoo.com logoU.S. jury sides with Amphastar over Momenta in drug patent trial
finance.yahoo.com - July 21 at 5:25 PM
americanbankingnews.com logoZacks: Analysts Anticipate Amphastar Pharmaceuticals, Inc. (AMPH) Will Announce Quarterly Sales of $60.81 Million
www.americanbankingnews.com - July 21 at 3:08 PM
reuters.com logoMomenta seeks $938 million from Amphastar at drug patent trial's end - Reuters
www.reuters.com - July 20 at 10:15 PM

Social

Chart

Amphastar Pharmaceuticals (AMPH) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff